Capital International Investors Has $716.66 Million Stake in Johnson & Johnson $JNJ

Capital International Investors lifted its stake in Johnson & Johnson (NYSE:JNJ) by 545.6% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,865,050 shares of the company’s stock after purchasing an additional 3,266,354 shares during the period. Capital International Investors owned 0.16% of Johnson & Johnson worth $716,657,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of JNJ. Vanguard Group Inc. lifted its stake in shares of Johnson & Johnson by 1.3% during the second quarter. Vanguard Group Inc. now owns 237,047,859 shares of the company’s stock valued at $36,209,060,000 after acquiring an additional 3,085,180 shares during the period. Geode Capital Management LLC raised its holdings in Johnson & Johnson by 2.1% during the 2nd quarter. Geode Capital Management LLC now owns 60,609,476 shares of the company’s stock worth $9,227,988,000 after purchasing an additional 1,225,676 shares during the last quarter. Norges Bank bought a new stake in Johnson & Johnson during the 2nd quarter worth about $4,877,174,000. Bank of New York Mellon Corp lifted its position in Johnson & Johnson by 3.5% during the 3rd quarter. Bank of New York Mellon Corp now owns 24,637,649 shares of the company’s stock valued at $4,568,313,000 after purchasing an additional 835,146 shares during the period. Finally, Legal & General Group Plc boosted its stake in shares of Johnson & Johnson by 2.8% in the 3rd quarter. Legal & General Group Plc now owns 19,450,064 shares of the company’s stock valued at $3,606,431,000 after purchasing an additional 532,790 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Transactions at Johnson & Johnson

In related news, EVP Timothy Schmid sold 1,322 shares of the stock in a transaction that occurred on Friday, February 20th. The stock was sold at an average price of $245.66, for a total transaction of $324,762.52. Following the completion of the sale, the executive vice president directly owned 25,447 shares of the company’s stock, valued at approximately $6,251,310.02. This represents a 4.94% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Vanessa Broadhurst sold 6,197 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the sale, the executive vice president owned 23,003 shares in the company, valued at $5,598,700.17. This trade represents a 21.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 30,142 shares of company stock worth $7,360,528. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Trading Up 0.5%

Shares of NYSE JNJ opened at $243.75 on Wednesday. Johnson & Johnson has a twelve month low of $141.50 and a twelve month high of $251.71. The stock has a market cap of $587.41 billion, a price-to-earnings ratio of 22.06, a P/E/G ratio of 2.40 and a beta of 0.34. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.48. The company’s fifty day moving average is $229.80 and its 200-day moving average is $205.27.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Saturday, January 31st. The company reported $2.46 EPS for the quarter. The business had revenue of $24.28 billion during the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. Equities research analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th were given a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.1%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 47.06%.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA approved the combination of TECVAYLI (teclistamab‑cqyv) plus DARZALEX FASPRO for relapsed/refractory multiple myeloma, supported by Phase‑3 MajesTEC‑3 data showing improved progression‑free and overall survival — a meaningful commercial and clinical win that can expand J&J’s oncology revenue and shift treatment patterns earlier in the therapy line. How FDA Approval of TECVAYLI and DARZALEX FASPRO Combo At Johnson & Johnson (JNJ) Has Changed Its Investment Story
• Positive Sentiment: EU expanded approval of Akeega to include BRCA‑mutated metastatic hormone‑sensitive prostate cancer — label expansion that can broaden addressable market in oncology and supports incremental sales in EMEA. JNJ Gets EU Nod for Expanded Use of Akeega in Prostate Cancer
• Neutral Sentiment: Management’s presentation at the Barclays Global Healthcare Conference provides updated commentary on pipeline priorities and commercialization plans — useful for tracking execution but not a discrete catalyst by itself. Johnson & Johnson (JNJ) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
• Neutral Sentiment: Analyst/valuation pieces and recent share‑price momentum have revived investor attention — this could sustain trading interest but depends on execution and revenue contribution from recent approvals. Assessing Johnson & Johnson (JNJ) Valuation As Recent Share Moves Revive Investor Interest
• Negative Sentiment: Short interest rose ~20.8% in February to ~25.09M shares (≈1.0% of shares), raising the short‑interest ratio to ~2.5 days — a small bearish signal that can add volatility if sentiment turns.
• Negative Sentiment: Two J&J units agreed to pay about $65M to settle a Tracleer antitrust class action — a modest cash cost relative to J&J’s size but a legal/expense item to note. Johnson & Johnson (JNJ) Units to Pay $65 Million in Tracleer Antitrust Class Action Settlement, Reuters Reports

Analysts Set New Price Targets

JNJ has been the subject of a number of recent research reports. HSBC boosted their price target on shares of Johnson & Johnson from $240.00 to $265.00 and gave the stock a “buy” rating in a research note on Friday, January 30th. Bank of America reiterated a “neutral” rating on shares of Johnson & Johnson in a research report on Monday, March 2nd. Royal Bank Of Canada raised their price target on Johnson & Johnson from $240.00 to $255.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 3rd. UBS Group reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Monday, January 5th. Finally, TD Cowen increased their target price on Johnson & Johnson from $222.00 to $250.00 and gave the company a “buy” rating in a research note on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $234.87.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.